Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Details Bicyclic pyrazolyl and imidazolyl compounds and uses thereof Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

2006-12-19

2006-12-19

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S220000, C514S221000, C540S490000, C540S497000, C540S498000, C540S502000

Reexamination Certificate

active

07151097

ABSTRACT:
Compounds of Formula (I) are described herein.The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.

REFERENCES:
patent: 2004/0077650 (2004-04-01), Dow
patent: 2004/0092520 (2004-05-01), Griffith
patent: 2004/0122074 (2004-06-01), Dow et al.
patent: 2004/0157838 (2004-08-01), Griffith
patent: 2004/0157839 (2004-08-01), Griffith
patent: 2004/0214837 (2004-10-01), Griffith et al.
patent: 2004/0214838 (2004-10-01), Carpino et al.
patent: 2004/0214855 (2004-10-01), Carpino et al.
patent: 2004/0214856 (2004-10-01), Carpino et al.
patent: 2004/0224970 (2004-11-01), Smith et al.
patent: 2004/0235926 (2004-11-01), Sakya
patent: 2004/0248881 (2004-12-01), Carpino et al.
patent: 2004/0259887 (2004-12-01), Dow
patent: 2005/0026983 (2005-02-01), Carpino
patent: WO 0158869 (2001-02-01), None
patent: WO 03020217 (2002-08-01), None
patent: WO 03027114 (2002-09-01), None
patent: WO 03080609 (2003-03-01), None
patent: WO 04094421 (2004-04-01), None
patent: WO 04094429 (2004-04-01), None
patent: WO 04098520 (2004-04-01), None
Pertwee, Roger,Exp. Opin. Invest. Drugs,“Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development”, vol. 9(7), pp. 1553-1571 (2000).
Glushkov, R., et al.Study of Lactams,“Reactionof 2, 3-Dioxo-4-(N,N-Dimethylaminomethylene) Hexahydroazepine with Hydrazine and its Derivatitves”, vol. 9 , pp. 1248-1251 (1978).
Beardsley, P.M., et al.,Behavioural Pharmacology,“Current Evidence Supporting a Role of Cannabinold CB1 Receptor (CB1R) Antagonists as Potential Pharmacotherapies for Drug Abuse Disorders”, vol. 16, pp. 275-296 (2005).
Bermudez-Siva, F., et al.,Journal of Pharmacology,“Activation of Cannabinoid CB1 Receptors Induces Glucose Intolerance in Rats”, vol. 531, pp. 282-284 (2006).
Brittain. H.G.,Drugs and the Pharmaceutical Sciences,“Polymorphism in Pharmaceutical Solids”, vol. 95, pp. 202-207 (1999).
Brodie, B.B.,Life Sciences,“Rimonabant: The First Therapeutically Relevant Cannabinold Antagonist”, vol. 77, pp. 2339-2350 (2005).
Cao, X, et al., A Selective Cannabinoid CB1 Antagonist Increases Levodopa Responses in Parkinsonlan Monkeys.
Chambers, A.P., et al.,Physiology&Behavior,“Cannabinoid (CB1) Receptor Antagonist, AM 251, causes a Sustained Reduction of Daily Food Intake in the Rat”, vol. 82, pp. 863-869 (2004).
Chaperon, F., et al.,Psychopharmacology,“Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats”, vol. 135, pp. 324-332 (198).
Cohen, C., et al.,Behavioural Pharmacology,SR141716, A Central Cannabinoid (CBI) Receptor Antagonist, Blocks the Motivational and Dopamine-Releasing Effects of Nicotine in Rats, vol. 13, pp. 451-463 (2002).
Croci, T., et al.,British Journal of Pharmacology,“Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor—αin the Gut and Systemic Anti-Inflammatory Activity of SR 141716 (Rimonabant) in Rodents”, vol. 140, pp. 115-122 (2003).
De Vries, T.J., et al.,Trends in Pharmacological Sciences,“Cannabinoid CB1 Receptors Control Conditioned Drug Seeking”, vol. 26 No. 8, pp. 420-426 (2005).
Di Marzo, V.,TRENDS in Pharmacological Sciences,“A Brief History of Cannabinoid and Endocannabinoid Pharmacology as Inspired by the Work of British Scientists”, vol. 20 No. 20 pp. 1-7 (2006).
Di Marzo, V., et al.,The FASEB Journal,“Enhanced Levels of Endogenous Cannabinoids in the Globus Pallidus are Associated with a Reduction in Movement in an Animal Model of Parkinson's Disease”, vol. 14, pp. 1432-1438 (2000).
Fernandez, J.R., et al.,Current Opinion in Investigational Drugs,“Rimonabant Sanofl-Synthelabo”, vol. 5, No. 4, pp. 430-435 (2004).
Ferrer, B., et al.,European Journal of Neuroscience,“Effects of Levodopa on Endocannabinoid Levels in Rat Basal Ganglia”: Implications for the Treatment of Levodopa-Induced Dyskinesias, vol. 18, pp. 1607-1614 (2003).
Griebel, G., et al.,Biol. Psychiatry,Effects of the Cannabinoid CB1 Receptor antagonist Rimonabant In Models of Emotional.
Lange, J., et al.,Drug Discovery Today“Medicinal Chemistry Strategies to CB1 Cannabinoid Receptor Antagonists”, vol. 10, No. 10, pp. 693-702 (2005).
Le Foll, B., et al.,NeuroReport,“Reimonabant, a CB1 Antagonist, Blocks Nicotine-Conditioned Place Preferences”, vol. 15, No. 13, pp. 2139-2143 (2004).
Mansbach, R.S., et al.,Psychopharmacology,“Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behaviour of Pigeons and Rats”, vol. 124, pp. 315-322 (1996).
Mas-Nieto, M., et al.,British Journal of Pharmacology,“Reduction of Opioid Dependence by the CB1 antagonist SR141716A in Mice: Evaluation of the Interest in Pharmacology of Opioid Addiction”, vol. 132, pp. 1809-1816 (2001).
Mechoulam, R., et al.,TRENDS in Pharmacological Sciences,“Cannabis and Alcohol—A Close Friendship”, vol. 24, No. 6, pp. 266-268 (2003).
Muccloli, G.G., et al.,Current Medicinal Chemistry,“Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors”, vol. 12, pp. 1361-1394 (2005).
Pagotto, U., et al.,Endocrine Reviews,“The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance”, vol. 27, No. 1, pp. 73-100 (2006).
Pagotto, U., et al.,Current Opinion in Endocrinology&Diabetes,“the Role of the Endocannabinoid Pathway in Metabolism and Diabetes”, vol. 13, pp. 171-178 (2006).
Poncelet, M., et al.,Psychopharmacology,“Blockade of Cannabinoid (CB1) Receptors By SR 141716 Selectively Antagonizes Drug-Induced Reinstatement of Exploratory Behaviour in Gerbils”, vol. 144, pp. 144-150 (1999).
Sanudo-Pena, M., et al,Neuroscience Letters,“Endogenous Cannabinoids As an Aversive or Counter-Rewarding System in the Rat”, vol. 223, pp. 125-128 (1997).
Smith, R.A., et al.,IDrugs,“Recent Advances in the Research and Development of CB1 Antagonists”, vol. 8, No. 1, pp. 53-66 (2005).
Thakur, G.A., et al.,Mini-Reviews in Medicinal Chemistry,“CB1 Cannabinoid Receptor Ligands”, vol. 5, pp. 631-640 (2005).
Van Der Stell, M., et al.,The FASEB Journal,“A Role For Endocannabinoids in the Generation of Parkinsonism and Levodopa-Induced Dyskinesia in MPTP-Lesioned Non-Human Primate Models of Parkinson's Disease”, vol. 19, pp. 1140-1142 (2005).
Van Gaal, L., et al.,Lancet,“Effects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-year Experience from the RIO-Europe Study”, vol. 365, pp. 1389-1397 (2005).
Witkin, J.M., et al.,TRENDS in Pharmacological Sciences,“A Therapeutic Role for Cannabinoid CB1 Receptor Antagonists in Major Depressive Disorders”, vol. 26, No. 12, pp. 609-617 (2005).
Wolff, M., et al.,European Journal of Pharmcology,“SR141716A, A Cannabinoid CB1 Receptor Antagonist, Improves Memory in a Delayed Radial Maze Task”, vol. 477, pp. 213-217 (2003).
Louis, C., et al.,Psychopharmacology,“Surinabant, a New CB1 Receptor Antagonist, Displays Efficacy in Animal Models of Attention Deficit/Hyperactivity Disorder”, vol. 30, S173, Abstract 77 (2005).

Affiliated with

Also associated with

Rating

Bicyclic pyrazolyl and imidazolyl compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic pyrazolyl and imidazolyl compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic pyrazolyl and imidazolyl compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3664466